2020 Virtual SABCS Exhibitors
Product Theatre Schedule
Wednesday, December 9, 10:00 am
Integrating MammaPrint and BluePrint into Pre- and Post-Operative Patient Care
presented by Agendia
Wednesday, December 9, 12:00 pm
TUKYSA® (tucatinib): A Treatment Option for patients with HER2+ metastatic breast cancer (MBC)
presented by Seattle Genetics
Wednesday, December 9, 2:00 pm
Preventing Bone Complications in Patients with Solid Tumors Metastatic to Bone
presented by Amgen
Thursday, December 10, 10:00 am
A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely To Do Worse
presented by Lilly Oncology
Thursday, December 10, 12:00 pm
Yes or No? Answering chemotherapy and endocrine therapy questions through a case-based discussion with the Oncotype DX® test
presented by Exact Sciences (formerly Genomic Health)
Thursday, December 10, 2:00 pm
Exploring the Benefits of FDA Approved Tissue and Liquid-Based Comprehensive Genomic Profiling Tests for Patients with Advanced Breast Cancer
presented by Foundation Medicine
Thursday, December 10, 4:00 pm
Evidence supporting use of a Biosimilar in Cancer Treatment
presented by Merck
Friday, December 11, 12:00 pm
Selecting a First-in-Class Oral Therapy for Patients With HR+/HER2- Metastatic Breast Cancer
presented by Pfizer
Friday, December 11, 2:00 pm
Updates on the Treatment of Patients with Unresectable or Metastatic HER2+ Breast Cancer who Previously Received Anti-HER2 Therapies
presented by Daiichi-Sankyo
Friday, December 11, 4:00 pm
A Treatment Option for Patients With Certain Types of Advanced TNBC
presented by Merck
7,987 Symposium attendees + 176 Media + 623 Exhibitors, Non-Exhibiting Sponsors & their Support Staff = 8,786 total attendance. 46% came from 84 countries outside the USA. Click here
to view an audited 2019 SABCS registration report, which includes further details.
Code of Conduct
Exhibitors agree to adhere to the compliance guidelines and
codes of conduct governing the interactions of drug and device
manufacturers with healthcare professionals as promulgated by the U.S. Food and Drug Administration, the Department of
Health and Human Services Office of the Inspector General, the
Pharmaceutical Research and Manufacturers of America (PhRMA)
and the Advanced Medical Technology Association AdvaMed.
- Sharing of booth space with an unrelated company is not permitted.
- “Subleasing” of booth space to an unrelated company is not permitted.
Hours may be subject to change.
Complimentary exhibit area only registrations entitle the registrant to access the virtual exhibit area only. Full registration is required in order to attend SABCS virtual programs.